Blood Plasma Derivatives Market

• In June 2023: Grigols (Spain) Group and Canadian Plasma Resources sign a contract to guarantee the availability of plasma in Canada. Grifols and their agreement state that by 2026, Grifols will produce 2.4 million grams of Ig medications annually after progressively growing their Canadian plasma supply.
• In April 2023: Biotest AG (Germany) opens its 10th plasma collection centre in Germany. Biotest is thus continuing the planned expansion of its own donation centres in Europe to contribute to more plasma collection after the plasma shortage in Germany and Europe.

In this report, The Blood Plasma Derivatives Market Has Been Segmented By Type, Application and Geography.

Blood Plasma Derivatives Market, Segmentation by Type

The Blood Plasma Derivatives Market has been segmented by Type into FactorVIII Concentrate, FactorIX Concentrate, Albumin, ImmuneGlobulins, Anti-Thrombin III Concentrate, Fresh Frozen Plasma (FFP) and Others.

Factor VIII Concentrate

Factor VIII Concentrate is a vital blood plasma derivative primarily used in managing Hemophilia A, making up roughly 35-40% of the overall market share. It plays an indispensable role in clotting factor replacement therapies, significantly minimizing bleeding risks. Market growth is fueled by rising disease awareness and enhanced diagnostic capabilities globally.

Factor IX Concentrate

Occupying approximately 10-15% of the plasma derivatives market, Factor IX Concentrate is essential for treating Hemophilia B. This concentrate aids in replenishing deficient clotting factors, improving patient outcomes. Increasing prevalence of hemophilia and better treatment access in emerging economies are key growth drivers.

Albumin

Accounting for about 20-25% of the market, Albumin is extensively used as a plasma volume expander, particularly in surgical and critical care settings. Its effectiveness in maintaining oncotic pressure and blood volume makes it indispensable in healthcare. The rising number of surgeries and chronic illness incidences are propelling demand.

Immune Globulins

Immune Globulins represent a significant segment, holding around 15-20% market share, due to their widespread use in treating immune deficiencies and autoimmune diseases. These derivatives offer passive immunity and immunomodulatory effects, with growth driven by a growing patient base and advancements in therapeutic techniques.

Anti-Thrombin III Concentrate

Making up roughly 5-7% of the market, Anti-Thrombin III Concentrate is crucial for preventing blood clots, particularly in patients with antithrombin deficiency. It plays a key role in coagulation control during surgeries and critical care. Increasing awareness and diagnosis of clotting disorders contribute to steady market expansion.

Fresh Frozen Plasma (FFP)

Fresh Frozen Plasma accounts for about 8-10% of the market, used mainly for replacing clotting factors in trauma and liver disease patients. Its quick availability and effectiveness in emergency treatment scenarios make it highly valuable. The rise in trauma incidents and liver disorders are major market influencers.

Others

This segment comprises lesser-known plasma derivatives such as fibrinogen and prothrombin complex concentrates, making up about 3-5% of the total market. Used in specialized clinical conditions, ongoing innovations in plasma fractionation are expected to enhance this segment’s growth in the coming years.

Blood Plasma Derivatives Market, Segmentation by Application

The Blood Plasma Derivatives Market has been segmented by Application into HIV, HemophiliaA, HemophiliaB, HepatitisB, HepatitisC, Bleedingdisorders, Hypogammaglobulinemia, ImmunodeficiencyDiseases and Others.

HIV

Plasma derivatives play a significant role in managing HIV-related complications, helping to enhance immune function and fight infections. This application holds about 10-12% of the market, with growth driven by improved therapeutic options and rising patient awareness worldwide.

Hemophilia A

Representing nearly 30-35% of the blood plasma derivatives market, Hemophilia A treatment relies heavily on clotting factor replacements such as Factor VIII concentrate. These therapies are crucial for preventing bleeding events and improving patients’ daily lives.

Hemophilia B

Hemophilia B applications make up around 10-15% of the market, primarily using Factor IX concentrates. These plasma-derived therapies are vital for clotting factor replacement, significantly reducing bleeding risks for affected individuals.

Hepatitis B

Plasma-derived immunoglobulins used in preventing and managing Hepatitis B infections constitute about 8-10% of the market. These products are essential in post-exposure prophylaxis and high-risk patient care, supporting global efforts to control the disease.

Hepatitis C

Although antiviral treatments have advanced, plasma derivatives remain relevant in Hepatitis C management, accounting for roughly 5-7% of the market. They provide immune support and aid in managing complications in affected patients.

Bleeding Disorders

Bleeding disorders account for an estimated 20-25% of plasma derivatives usage. This broad category includes various coagulation factors and plasma products that help control bleeding and promote hemostasis in patients with diverse clotting deficiencies.

Hypogammaglobulinemia

Approximately 5-7% of the market involves treating hypogammaglobulinemia with plasma-derived immunoglobulins. These therapies are essential in restoring antibody levels and preventing infections in immunocompromised patients.

Immunodeficiency Diseases

Holding about 8-10% of the market, plasma derivatives are widely used in treating different immunodeficiency disorders. These immune globulins enhance immune defenses and reduce infection risks in vulnerable populations.

Others

Other specialized applications represent about 3-5% of the plasma derivatives market. These include rare conditions and emerging uses that benefit from ongoing innovations in plasma fractionation and therapy development.

Blood Plasma Derivatives Market, Segmentation by End-Use

The Blood Plasma Derivatives Market has been segmented by End-Use into Hospitals & Clinics, Blood Transfusion Centers, Diagnostic Centers and Others.

Hospitals & Clinics

Hospitals and clinics form the largest end-use segment in the blood plasma derivatives market, contributing about 50-60% of the total share. These facilities extensively use plasma derivatives for treating bleeding disorders, immune deficiencies, and during surgeries. The increasing patient influx and advanced healthcare infrastructure are key factors sustaining the high demand.

Blood Transfusion Centers

Making up nearly 20-25% of the market, blood transfusion centers play a crucial role in delivering plasma derivatives for blood component therapies and replacement treatments. The segment’s growth is driven by heightened awareness of safe transfusion practices and increasing demand for quality blood products.

Diagnostic Centers

Diagnostic centers hold around 10-12% of the market and primarily use plasma derivatives for immunological and hematological testing. Technological advancements in diagnostics and the need for accurate laboratory assessments are propelling growth in this sector.

Others

The “Others” category includes specialized healthcare providers and research organizations, accounting for 8-10% of the market. Expanding research applications and innovations in plasma-based therapies contribute to steady growth within this segment.

Blood Plasma Derivatives Market, Segmentation by Geography

In this report, the Blood Plasma Derivatives Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Blood Plasma Derivatives Market Share (%), by Geographical Region

North America

North America dominates the Blood Plasma Derivatives Market with an estimated share of 35-40%. The region’s advanced healthcare infrastructure, high incidence of chronic diseases, and robust research and development activities fuel this growth. Additionally, increased patient awareness and favorable reimbursement frameworks enhance market prospects.

Europe

Europe captures about 25-30% of the market, supported by strong healthcare systems and numerous government initiatives promoting plasma therapies. Technological advancements in plasma fractionation and an increasing patient base with bleeding disorders further drive market expansion across the continent.

Asia Pacific

Emerging as a high-growth market, Asia Pacific holds a 15-20% share due to rising healthcare spending, improved medical facilities, and growing cases of immunodeficiency and bleeding disorders. Enhanced patient education and expanded treatment availability are key contributors to the region’s rapid market growth.

Middle East and Africa

With a 5-7% market share, the Middle East and Africa region is witnessing growth due to enhancements in healthcare infrastructure and heightened efforts to manage infectious diseases. However, limited access to advanced plasma therapies and economic challenges temper the region’s market potential.

Latin America

Latin America’s blood plasma derivatives market accounts for 5-8% of the global share. Growing government initiatives, rising patient awareness, and improved healthcare access underpin steady growth. Despite budgetary and access limitations, the market continues to make gradual advancements.

This report provides an in depth analysis of various factors that impact the dynamics of Global Blood Plasma Derivatives Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunities Analysis

Drivers:

• Increasing Prevalence of Chronic Diseases
• Advancements in Medical Technology
• Rising Geriatric Population

• Growing Awareness and Adoption of Plasma-Derived Therapies - The growing awareness and adoption of plasma-derived therapies are significant drivers of the global blood plasma derivatives market. Over the past decade, there has been a concerted effort by healthcare providers, patient advocacy groups, and industry players to educate both the medical community and the general public about the benefits of plasma-derived products. These therapies are crucial in managing a range of medical conditions, including immunodeficiencies, autoimmune diseases, and bleeding disorders, which has underscored their importance in modern medicine.

  One of the key factors contributing to this increased awareness is the dissemination of information through various channels, including medical conferences, seminars, and awareness campaigns. These initiatives help in demystifying plasma-derived therapies, making them more accessible and understandable to both patients and healthcare practitioners. Additionally, success stories and case studies highlighting the efficacy of these therapies in improving patient outcomes have played a pivotal role in building trust and acceptance.

  The adoption of plasma-derived therapies is being accelerated by advancements in diagnostic technologies, which facilitate early and accurate diagnosis of conditions treatable with these products. This early diagnosis allows for timely intervention with plasma-derived therapies, improving patient prognosis and quality of life. The integration of these therapies into treatment protocols and guidelines by health authorities and professional medical associations also lends credibility and encourages their broader use.

  The ongoing improvements in the safety and efficacy of plasma-derived products, driven by rigorous research and development efforts, have bolstered confidence among healthcare providers. Innovations in plasma fractionation and purification techniques have significantly reduced the risk of transfusion-related complications, making these therapies safer for patients. This enhanced safety profile, coupled with proven clinical benefits, is fostering greater adoption across various healthcare settings.

Restraints:

• Supply Constraints and Donor Dependency
• High Costs of Plasma-Derived Therapies
• Regulatory and Compliance Challenges

• Risk of Transfusion-Transmitted Infections - The risk of transfusion-transmitted infections (TTIs) remains a significant restraint in the global blood plasma derivatives market. Despite advancements in screening and purification technologies, the potential for infections such as hepatitis B, hepatitis C, HIV, and other emerging pathogens continues to be a critical concern. This risk can deter both donors and recipients, impacting the overall supply and demand for plasma-derived products.

  One of the primary challenges is the window period of infections, during which the pathogen may be present in the donor's blood but not detectable by current screening methods. This gap can lead to the inadvertent transmission of infections through plasma-derived therapies. Although sophisticated nucleic acid testing (NAT) and other advanced screening techniques have significantly reduced this risk, no system is entirely foolproof. The possibility of new, unknown pathogens emerging further complicates the safety landscape.

  The process of plasma collection involves multiple donors, which increases the complexity of ensuring safety. Each batch of plasma-derived products is derived from pooled plasma of thousands of donors, raising the stakes for rigorous testing and quality control. The extensive and costly procedures required to mitigate TTIs, such as pathogen inactivation and advanced viral testing, can also impact the overall cost structure and availability of these therapies.

  Public perception and trust play a crucial role in the adoption of plasma-derived products. Historical instances of TTI outbreaks, although rare in recent times, have left a lasting impression on public consciousness. This lingering apprehension can influence patient and healthcare provider decisions, potentially limiting the market's growth. Efforts to rebuild and maintain trust through transparent communication, continuous monitoring, and prompt action in case of any safety concerns are essential.

Opportunties:

• Expansion in Emerging Markets
• Development of Novel Plasma-Derived Therapies
• Strategic Collaborations and Acquisitions

• Technological Innovations in Plasma Collection and Processing - Technological innovations in plasma collection and processing are driving significant advancements in the global blood plasma derivatives market. These innovations are enhancing the efficiency, safety, and scalability of plasma-derived products, addressing some of the critical challenges faced by the industry. One of the key areas of development is the improvement in plasma collection techniques, which now include automated apheresis machines. These machines enable the selective collection of plasma while returning other blood components to the donor, making the process quicker and less taxing on donors, thereby encouraging higher donation rates.

  Advancements in processing technologies have also revolutionized the plasma fractionation process, which is essential for extracting specific proteins and other valuable components from plasma. Modern fractionation techniques, such as cryoprecipitation and chromatographic purification, have significantly increased the yield and purity of plasma-derived products. These methods ensure that the final products are free from contaminants and have higher therapeutic efficacy. Moreover, innovations in viral inactivation and removal processes have enhanced the safety profile of these products by effectively eliminating pathogens, thus reducing the risk of transfusion-transmitted infections.

  Another notable innovation is the development of recombinant DNA technology and monoclonal antibody techniques, which have paved the way for the production of recombinant plasma proteins. These recombinant products mimic naturally occurring plasma proteins but are produced in controlled laboratory environments, ensuring consistent quality and reducing dependence on human donors. This shift not only addresses supply constraints but also opens new avenues for the treatment of rare and complex diseases.

  The integration of digital technologies and data analytics into plasma collection and processing is also transforming the market. Advanced data management systems and real-time monitoring tools are improving the efficiency of plasma collection centers by optimizing donor scheduling, ensuring regulatory compliance, and maintaining high standards of product quality. Additionally, blockchain technology is being explored to enhance traceability and transparency in the plasma supply chain, ensuring that every step from donation to final product delivery is securely documented and verifiable.

Key players in Global Blood Plasma Derivatives Market include:

• Baxter BioScience
• Grifols
• CSL Behring
• ViroPharma
• Talecris Biotherapeutics

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis